YÜksel ÜrÜn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6775494/publications.pdf

Version: 2024-02-01

82 papers 1,245 citations

15 h-index 34 g-index

83 all docs 83 docs citations

83 times ranked 2401 citing authors

#	Article	IF	CITATIONS
1	Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. European Urology, 2014, 66, 42-54.	0.9	349
2	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
3	A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. European Journal of Cancer, 2020, 141, 92-104.	1.3	88
4	Cytoreductive nephrectomy in patients with metastatic nonâ€elearâ€eell renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, E67-74.	1.3	62
5	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	5.1	61
6	Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Supportive Care in Cancer, 2017, 25, 229-236.	1.0	53
7	Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine) Tj ETQq1 1 0.784314 rgBT /Overlo	ock 10 Tf 5 0.6	50 507 Td (Ai 41
8	Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. JCO Global Oncology, 2020, 6, 1248-1257.	0.8	33
9	Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2801-2803.	0.5	23
10	ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6097-6100.	0.5	21
11	Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG). Supportive Care in Cancer, 2016, 24, 3747-3755.	1.0	19
12	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 120-126.	2.0	19
13	The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. Journal of Oncology Pharmacy Practice, 2020, 26, 1110-1116.	0.5	19
14	Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab. Journal of Oncology Pharmacy Practice, 2020, 26, 1289-1294.	0.5	19
15	Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs. Critical Reviews in Oncology/Hematology, 2020, 145, 102822.	2.0	17
16	Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in <i>BRCA1</i> , <i>BRCA2</i> or <i>ATM</i> : Results from the PROfound study Journal of Clinical Oncology, 2021, 39, 27-27.	0.8	17
17	Assessing population diversity in phase <scp>III</scp> trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. International Journal of Cancer, 2021, 149, 1455-1462.	2.3	16
18	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate, 2015, 75, 1677-1681.	1.2	14

#	Article	IF	CITATIONS
19	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. European Urology Focus, 2016, 2, 633-639.	1.6	12
20	Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer. Supportive Care in Cancer, 2020, 28, 5235-5242.	1.0	12
21	Performing Only One Cardiovascular Reflex Test Has a High Positive Predictive Value for Diagnosing Autonomic Neuropathy in Patients with Chronic Renal Failure on Hemodialysis. Renal Failure, 2006, 28, 383-387.	0.8	11
22	Clinicopathological Features of Patients with Malignant Mesothelioma in a Multicenter, Case-Control Study: No Role for ABO-Rh Blood Groups. Asian Pacific Journal of Cancer Prevention, 2013, 14, 249-253.	0.5	11
23	Vaccination in oncology practice and predictors. Supportive Care in Cancer, 2017, 25, 2677-2682.	1.0	10
24	Reversible Edema in a Male Patient Taking Parenteral Pantoprazole Infusion for Pyloric Stenosis. Digestive Diseases and Sciences, 2006, 51, 121-122.	1.1	9
25	The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. Journal of Cancer Research and Clinical Oncology. 2022, 148, 3537-3546.	1.2	9
26	Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naÃ-ve breast cancer: real-life practice outcomes. Cancer Chemotherapy and Pharmacology, 2019, 83, 131-143.	1.1	8
27	Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. Journal of Oncology Pharmacy Practice, 2020, 26, 267-272.	0.5	8
28	Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. European Urology Focus, 2021, 7, 1061-1066.	1.6	8
29	A clinical dilemma amid COVID-19 pandemic: missed or encountered diagnosis of cancer?. Future Oncology, 2020, 16, 1879-1881.	1.1	8
30	Angiosarcoma related to immunosuppressive therapy 8 years after renal transplantation. Annals of Transplantation, 2011, 16, 138-140.	0.5	8
31	Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4129-4131.	0.5	8
32	Predictors of Outcome in Patients with Advanced Nonseminomatous Germ Cell Testicular Tumors. Asian Pacific Journal of Cancer Prevention, 2014, 15, 831-835.	0.5	8
33	Letter to the Editor: "Two Cases with Horseshoe Kidney in Association with Nephrotic Syndrome: Is There a Causal Relationship between Two Conditions?― Renal Failure, 2007, 29, 517-518.	0.8	7
34	Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma. Nuclear Medicine Communications, 2019, 40, 1243-1249.	0.5	7
35	Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. Journal of Oncology Pharmacy Practice, 2019, 25, 1658-1664.	0.5	7
36	Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature. Journal of Oncology Pharmacy Practice, 2020, 26, 1762-1764.	0.5	7

#	Article	IF	CITATIONS
37	Bradycardia due to Methylprednisolone Therapy. Journal of Clinical Rheumatology, 2004, 10, 230.	0.5	6
38	Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Journal of Oncology Pharmacy Practice, 2020, 26, 1583-1589.	0.5	6
39	Silent Celiac Disease Presenting With Polyarthritis. Journal of Clinical Rheumatology, 2010, 16, 195-196.	0.5	5
40	A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 972-981.	0.5	5
41	18F-Flourodeoxy glucose PET–computed tomography in testicular carcinoma: diagnostic and prognostic value. Nuclear Medicine Communications, 2019, 40, 1268-1274.	0.5	5
42	Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study. Journal of Gastrointestinal Cancer, 2022, 53, 870-879.	0.6	4
43	Activity of pemetrexed on brain metastases from non-small cell lung cancer: What is the mechanism?. Lung Cancer, 2009, 66, 399.	0.9	3
44	Risk factors for thrombosis risk in patients with cancer. Journal of Oncological Science, 2018, 4, 130-133.	0.1	3
45	Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?. Prostate International, 2021, 9, 1-5.	1.2	3
46	ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis. Future Oncology, 2021, 17, 349-357.	1.1	3
47	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 166, 103463.	2.0	3
48	Intraabdominal follicular dendritic cell sarcoma: a report of three cases and review of the literature. Tumori, 2013, 99, e65-9.	0.6	3
49	mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors. Future Virology, 2021, , .	0.9	2
50	Predictor of 68Ga PSMA PET/CT positivity in patients with prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 226-230.	0.4	2
51	Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future Oncology, 2021, 17, 4861-4869.	1.1	2
52	The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib. Future Oncology, 2022, 18, 1067-1076.	1.1	2
53	How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About "M-Neoadjuvant―and "M-Adjuvant�. Annals of Surgical Oncology, 2010, 17, 1970-1970.	0.7	1
54	Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation. Journal of Oncology Pharmacy Practice, 2021, 27, 1657-1664.	0.5	1

#	Article	IF	CITATIONS
55	ABO blood group and risk of lethal prostate cancer Journal of Clinical Oncology, 2014, 32, 69-69.	0.8	1
56	Targeted Agents and Resistance Mechanism in Renal Cell Cancer. Üroonkoloji Bülteni, 2019, 18, 73-79.	0.1	1
57	Oncologic Approaches for Bone Metastasis Related Pain. , 2020, 6, 11-16.		1
58	Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4129-31.	0.5	1
59	Isolated Pulmonary Metastasis Presenting with an CEA Elevation Five Years After Radical Prostatectomy UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2013, 23, 200-201.	0.1	0
60	Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response. Annals of Dermatology, 2013, 25, 504.	0.3	0
61	Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?. Journal of Oncology Pharmacy Practice, 2019, 25, 2062-2063.	0.5	0
62	Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle?. Journal of Oncology Pharmacy Practice, 2021, 27, 450-452.	0.5	0
63	Changes in Metastatic Castration Sensitive Prostate Cancer. Üroonkoloji Býlteni, 2021, 20, 1-6.	0.1	0
64	Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. Üroonkoloji Bülteni, 2021, 20, 96-106.	0.1	0
65	In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice?. European Urology Oncology, 2021, 4, 515-516.	2.6	0
66	Response to letter entitled: Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19. European Journal of Cancer, 2021, 152, 248-249.	1.3	0
67	Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine) Tj ETQq1 1 0.784314 rgBT /OverRefractory Lymphoma Blood, 2007, 110, 4438-4438.	lock 10 Tf 0.6	50 267 Td (/ 0
68	Predictors of outcome in patients with advanced nonseminamatous germ cell testicular tumors Journal of Clinical Oncology, 2014, 32, e15528-e15528.	0.8	0
69	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis Journal of Clinical Oncology, 2015, 33, 351-351.	0.8	0
70	Can primary tumor localization predict the which patient will have benefit from addition of taxanes to platin-5-FU based regimens in metastatic gastric cancer. Multi center retrospective analysis from Turkey, Society of Turkish Oncology Group study Journal of Clinical Oncology, 2015, 33, e15030-e15030.	0.8	0
71	Persistent postmastectomy pain syndrome and posttraumatic stress disorder among breast cancer survivors (ORTHUS study): A study of the palliative care working committee of the Turkish Oncology Group (TOG) Journal of Clinical Oncology, 2016, 34, e21702-e21702.	0.8	0
72	Severe drug interactions and potentially inappropriate medication usage in elderly patients with cancer Journal of Clinical Oncology, 2016, 34, 10056-10056.	0.8	0

#	Article	IF	CITATIONS
73	Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation. Gulhane Medical Journal, 2018, 60, 130.	0.2	0
74	Place in Concomitant Use with Anti-EGFR Radiotherapy in Locally Advanced Head and Neck Cancer Treatment. Meandros Medical and Dental Journal, 2018, 19, 95-98.	0.1	0
75	Independent prognostic value of inflammation in metastatic pancreatic cancer Journal of Clinical Oncology, 2018, 36, e16212-e16212.	0.8	0
76	Merkel cell carcinoma in Turkey: A multicentric study Journal of Clinical Oncology, 2018, 36, e21591-e21591.	0.8	0
77	Positron Emission Tomography in Renal Cell Carcinoma. Üroonkoloji Bülteni, 2018, 17, 68-72.	0.1	0
78	Nuclear Medicine Applications in Diagnosis of Urological Tumors. Üroonkoloji Bülteni, 2019, 18, 80-88.	0.1	0
79	Efficacy of Chemotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer Patients - Do Homologous Recombination Deficiency Affect the Outcomes?. Üroonkoloji Bülteni, 2020, 19, 175-176.	0.1	0
80	Merkel cell carcinoma in Turkey: A multicentric study. Journal of Cancer Research and Therapeutics, 2021, 17, 1525.	0.3	0
81	Key considerations and common adverse events for HIV-positive patients withÂcancer treated with immune checkpoint inhibitors. Future Oncology, 2022, 18, 413-416.	1.1	0
82	Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience. Journal of Ankara University Faculty of Medicine, 2022, 75, 103-106.	0.0	0